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770Mosaic Activating Mutations in GNA11 and
GNAQ Are Associated with Phakomatosis
Pigmentovascularis and Extensive Dermal
Melanocytosis
Anna C. Thomas1,18, Zhiqiang Zeng2,18, Jean-Baptiste Rivie`re3,18, Ryan O’Shaughnessy4,
Lara Al-Olabi1, Judith St.-Onge3, David J. Atherton5, He´le`ne Aubert6, Lorea Bagazgoitia7,
Se´bastien Barbarot6, Emmanuelle Bourrat8,9, Christine Chiaverini10, W. Kling Chong11,
Yannis Duffourd3, Mary Glover5, Leopold Groesser12, Smail Hadj-Rabia13, Henning Hamm14,
Rudolf Happle15, Imran Mushtaq16, Jean-Philippe Lacour10, Regula Waelchli5, Marion Wobser14,
Pierre Vabres3,17,19, E. Elizabeth Patton2,19 and Veronica A. Kinsler1,5,19Common birthmarks can be an indicator of underlying genetic disease but are often overlooked. Mongolian
blue spots (dermal melanocytosis) are usually localized and transient, but they can be extensive, permanent,
and associated with extracutaneous abnormalities. Co-occurrence with vascular birthmarks defines a subtype
of phakomatosis pigmentovascularis, a group of syndromes associated with neurovascular, ophthalmological,
overgrowth, and malignant complications. Here, we discover that extensive dermal melanocytosis and pha-
komatosis pigmentovascularis are associated with activating mutations in GNA11 and GNAQ, genes that
encode Ga subunits of heterotrimeric G proteins. The mutations were detected at very low levels in affected
tissues but were undetectable in the blood, indicating that these conditions are postzygotic mosaic disorders.
In vitro expression of mutant GNA11R183C and GNA11Q209L in human cell lines demonstrated activation of
the downstream p38 MAPK signaling pathway and the p38, JNK, and ERK pathways, respectively. Transgenic
mosaic zebrafish models expressing mutant GNA11R183C under promoter mitfa developed extensive dermal
melanocytosis recapitulating the human phenotype. Phakomatosis pigmentovascularis and extensive dermal
melanocytosis are therefore diagnoses in the group of mosaic heterotrimeric G-protein disorders, joining
McCune-Albright and Sturge-Weber syndromes. These findings will allow accurate clinical and molecular
diagnosis of this subset of common birthmarks, thereby identifying infants at risk for serious complications,
and provide novel therapeutic opportunities.
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Mongolian blue spots (or, more appropriately, dermal mela-
nocytosis) are common birthmarks, seen in up to 95% of
African neonates and approximately 10% of white Caucasians
(Cordova, 1981). As a result they are easily overlooked as a
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an oflat, dark-blue lesions with indistinct edges overlying the but-
tocks and lower back, which undergo spontaneous resolution
over a period of years.However, the appearances and behavior
are not always classic (Gupta and Thappa, 2013). Somedermal
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body surface, are more deeply pigmented, are better defined,Urology, Great Ormond Street Hospital for Children, London, UK; and
17Dermatology, Dijon University Hospital, Dijon, France
18 These authors contributed equally to this work.
19 These authors contributed equally to this work.
Correspondence: Veronica A. Kinsler, Genetics and Genomic Medicine, UCL
Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. E-mail:
v.kinsler@ucl.ac.uk or Elizabeth Patton, MRC Institute of Genetics and
Molecular Medicine, MRC Human Genetics Unit & Edinburgh Cancer
Research UK Centre, Edinburgh, UK. E-mail: e.patton@igmm.ed.ac.uk
Abbreviations: DNA, deoxyribonucleic acid; PPV, phakomatosis pigmento-
vascularis; SWS, Sturge-Weber syndrome; WT, wild type
Received 29 June 2015; revised 31 October 2015; accepted 2 November
2015; accepted manuscript published online 14 January 2016; corrected
proof published online 26 February 2016
s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
AC Thomas et al.
GNA11 and GNAQ Mosaicismand persist rather than resolve. These more atypical patterns of
dermal melanocytosis can be associated with anomalies such
as colocalized cleft lip (Igawa et al., 1994), ocular melanocy-
tosis (Teekhasaenee et al., 1990), ocular melanoma (Shields
et al., 2013), lysosomal storage disorders (Hanson et al.,
2003), or vascular birthmarks. This latter association then
falls under the diagnostic group of phakomatosis pigmento-
vascularis (PPV) (for clinical examples see Figure 1). Phako-
matosis pigmentovascularis is a group of sporadic disorders of
unknown frequency, defined by the co-occurrence of
pigmentary and vascular birthmarks and subclassified clini-
cally by the exact cutaneous phenotypes (Supplementary
Table S1 online) (Happle, 2013; Hasegawa and Yasuhara,
1979; Ota et al., 1947). Whether the subtypes are distinct
disorders or variable expressions of a single disorder has not
been clear as the molecular and developmental pathogenesis
of PPV has been unknown. The hypothesis of non-allelic twin
spotting was previously expounded to explain the co-
occurrence of two disparate birthmarks (Danarti and Happle,
2003) but was recently retracted by the author because of
lack of supporting molecular evidence (Happle, 2013).
Extracutaneous associations of PPV can be severe, including
scleral or intraocular melanocytosis (Shields et al., 2011),
glaucoma (Henry et al., 2013; Teekhasaenee and Ritch, 1997;
Vidaurri-de laCruz et al., 2003), intracerebral vascular or other
malformations leading to seizures and cognitive delay (Hall
et al., 2007; Shields et al., 2011; Tsuruta et al., 1999;
Vidaurri-de la Cruz et al., 2003), overgrowth of soft tissues orFigure 1. Clinical examples of dermatological, ophthalmological, and neurologi
and capillary malformation (port wine stain type) on the face, extensive dermal m
the right foot. (d) Bilateral scleral melanocytosis with bilateral glaucoma. Capilla
Axial T1-weighed magnetic resonance image of the brain at the level of the late
showing bilateral and asymmetrical thickening and enhancement of the pia matlimbs (Chhajed et al., 2010; Jeon et al., 2013; Vidaurri-de la
Cruz et al., 2003), and melanoma. The latter can arise in
choroid or conjunctiva, with melanocytoma of the optic disk
also described (Krema et al., 2013; Shields et al., 2011;
Teekhasaenee and Ritch, 1997; Tran and Zografos, 2005).
Without an understanding of the genetic pathogenesis of the
disease, targeted therapies for the congenital and neoplastic
aspects of the disease have been impossible.
When considering the genetic basis of extensive dermal
melanocytosis and of PPV, we hypothesized that these con-
ditions could be the result of a postzygotic mutation in a
member of the G-protein nucleotide binding protein alpha
subunit family. This hypothesis was generated by the rare
concurrent description of PPV with Sturge-Weber syndrome
(SWS) (Chhajed et al., 2010; Vidaurri-de la Cruz et al., 2003),
a vascular disorder with no pigmentary phenotype recently
found to be the result of postzygotic mosaicism for activating
mutations in GNAQ (Shirley et al., 2013). We also hypoth-
esized that an identical mutation could be present in both
types of birthmarks in PPV, secondary to a single mutation in
a pluripotent progenitor cell.
RESULTS
Missense GNA11 or GNAQ mutations were found in 8 of 11
patients tested. In each case, these mutations were detected
in affected skin (and in one case ocular tissue) at very low
levels and were undetectable in blood, indicating postzygotic
mosaicism (Table 1). When levels of mutant allele <1% werecal aspects of phakomatosis pigmentovascularis. (aec) Dermal melanocytosis
elanocytosis on the back and legs, and capillary malformation on the sole of
ry malformation and hemihypertrophy are just visible on right side of face. (e)
ral ventricles after administration of intravenous gadolinium contrast agent
er. (Written consent for publication obtained in all cases.)
www.jidonline.org 771
Table 1. Clinical phenotype and GNA11 and GNAQ genotypes with percentage mosaicism (where available)
of different samples from eight patients with PPV (patients 1e8) and three patients with extensive dermal
melanocytosis with no vascular phenotype (patients 9e11), showing postzygotic mosaicism
Patient Diagnosis
Pigmentary
skin lesion
Vascular skin
lesion Blood Other samples Result
1 PPV unclassifiable (I) type: capillary malformation
on face (including forehead), trunk; pigmentary
lesions on limbs, trunk; linear sebaceous nevus
on scalp; linear woolly hair; glaucoma; no
overgrowth or neurological abnormalities
GNA11 c.547C>T,
p.R183C 5.3%
WT 0.0% GNA11 p.R183C
mosaic
2 PPV cesioflammea (II) type: capillary malformation
on face (including forehead); scleral melanocytosis
(no dermal melanocytosis); no overgrowth or
ophthalmological or neurological abnormalities
GNA11 c.547C>A,
p. R183S (novel)
Buccal swab
GNA11 c.547C>A,
p.R183S 7.9%
Normal skin WT
GNA11 p.R183S
mosaic
3 PPV cesioflammea (II) type: capillary malformation
on face (including forehead), trunk, limbs; nevus
anemicus; dermal melanocytosis on trunk; scleral
melanocytosis; bilateral glaucoma; renal vascular
hypertension; hemihypertrophy; macrocephaly;
CNS MRI reveals enlarged supratentorial
subarachnoid space, enlarged lateral ventricles,
increased arachnoid vascular network,
asymmetrical venous flow, absence of pial angioma
GNAQ c.548G>A,
p.R183Q 6.4%
WT 0.0% Pigmented ocular
tissue GNAQ
c.548G>A,
p.R183Q 11.0%
GNAQ p.R183Q
mosaic
4 PPV cesioflammea (II) type: capillary malformation
on face (including forehead), trunk, limbs; dermal
melanocytosis on trunk, limbs; growth delay;
small teeth; developmental delay; no overgrowth
or ophthalmological or radiological neurological
abnormalities
GNAQ c.548G>A,
p.R183Q 5.0%
WT 0.0% GNAQ p.R183Q
mosaic
5 PPV cesioflammea (II) type: capillary malformation
on face (including forehead), trunk, foot; dermal
melanocytosis on face (including forehead),
trunk, limbs; seizures; moderate global
developmental delay; overgrowth; bilateral
glaucoma; Sturge-Weber syndrome-like pial
angioma on CNS MRI
WT 0.0% WT 0.0% WT 0.0% WT
6 PPV achromico-melano-marmorata type
(unclassifiable in both classifications):
hyper- and hypo-pigmentary and reticulate
vascular lesions affecting trunk, limbs;
undergrowth of one leg (both legs affected
by vascular lesions); no ophthalmological or
neurological abnormalities
GNA11 c.547C>T,
p.R183C
WT GNA11 p.R183C
mosaic
7 PPV spilorosea type (III): pigmentary and vascular
lesions affecting trunk, limbs but not face; no
overgrowth or ophthalmological or neurological
abnormalities
WT 0.0% WT 0.0% WT 0.0% WT
8 PPV cesiomarmorata type (V): pigmentary lesions on
trunk; vascular lesions on face (including
forehead), trunk, limbs; mild developmental
delay, but CNS MRI shows periventricular
leukomalacia consistent with premature delivery;
no overgrowth or ophthalmological abnormalities
GNA11
c.547C>T,
p.R183C 15.5%
GNA11 c.547C>T,
p.R183C 9.6%
WT 0.3%
same
mutation
GNA11 p.R183C
mosaic
9 Extensive and multiple dermal melanocytosis
affecting trunk and limbs; no overgrowth or
ophthalmological or neurological abnormalities
GNAQ
c.548G>A,
p.R183Q 2%
N/A WT 0.1%
same
mutation
GNAQ p.R183Q
mosaic
10 One large (>20 cm) dark, well-defined, persistent
flank dermal melanocytosis; no overgrowth or
ophthalmological or neurological abnormalities
GNAQ
c.626A>C,
p.Q209P 5.7%
N/A WT 0.1%
same
mutation
GNAQ p.Q209P
mosaic
11 Extensive and multiple dermal melanocytosis
affecting trunk; no overgrowth or
ophthalmological or neurological abnormalities
WT 0.0% N/A WT 0.0% WT
Abbreviations: CNS, central nervous system; MRI, magnetic resonance imaging; N/A, not applicable; PPV, phakomatosis pigmentovascularis; WT, wild type.
For coordinates and exact wild-type and mutant allele numbers, see Supplementary Table S2 online. When mutant allele detection is <1%, we cannot
confidently distinguish this from background noise despite the depth of coverage; therefore, these samples are assigned as WT.
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772detected in blood, these could not be distinguished from
background noise despite the substantial depth of coverage
(Supplementary Table S2 online) and were therefore called asJournal of Investigative Dermatology (2016), Volume 136wild type (WT). In the three patients with extensive dermal
melanocytosis, we identified mutations in GNAQ in two, one
c.548G>A, p.R183Q, and one c.626A>C, Q209P. In the eight
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GNA11 and GNAQ Mosaicismpatients with PPV, we identified somatic GNA11 mutations in
four, three at position c.547C>T, p.R183C, and one novel mu-
tation in the same codon c.547C>A, p.R183S. and GNAQ
mutations in two, both at position c.548G>A, p.R183Q
(Figure 2). Importantly there was conservation of mutation be-
tweenpigmentaryandvascular lesions ineachpatient forwhom
more than one skin biopsy was available (Table 1 and
Supplementary Table S2). Measured percentage of mosaicism
in skin samples was lowest at 1.5% using next-generation
sequencing mutant allele count as a percentage of the total
number of reads (Supplementary Table S2). None of these mu-
tations inGNA11 andGNAQ is described in the largest current
population database (Exome Aggregation Consortium, 2015).
For the in vitro transfection experiments, HEK293 cells were
transfected with vector, WT GNA11, or mutant GNA11 con-
structs encoding R183C and Q209L. Figure 3 shows results of
western blots for Flag, total GNA11, and the phosphorylated
and total p38, JNK, ERK and AKT in total protein lysates from
these cells. Analysis of the ratio of phosphorylated to total p38,
JNK, ERK and AKT normalized by the actin loading control
(from two replicates, pooled results ofWTcompared to those of
mutant) demonstrated increasedphosphorylationand therefore
activation of the p38MAPK pathway by the R183Cmutant andof ERK, p38 MAPK, and JNK pathways by Q209L, in keeping
with previous results for Q209L (Li et al., 2014). These results
were significant at the 0.05 level using a one-tailed t test.
GNA11R183C- and GNA11Q209L-expressing zebrafish
exhibited dark cutaneous patches of melanocytes by 1
month. When the mutant transgenic zebrafish reached
adulthood at 3 months, nearly all injected fish (n ¼ 17/18 for
R183C and n ¼ 16/16 for Q209L) developed large and
clearly visible pigmentary lesions (Figure 4a and b), recapit-
ulating the human phenotype of dermal melanocytosis. Wild-
type GNA11 expression in melanocytes also produced
mosaic animals with some pigmentary lesions (n ¼ 10/27);
however, these were usually smaller and less dark, suggesting
that the melanocyte lineage is highly sensitive to GNA11-
coupled receptor signaling. Histopathology revealed many
extra melanocytes in both the epidermis (over the scales, not
shown) and the dermis in the pigmentary lesion of mutant
GNA11R183C injected fish, with occasional involvement of
the underlying muscle (Figure 4c).
DISCUSSION
We sought to differentiate a subgroup of the common
birthmark dermal melanocytosis in infants who are at risk ofFigure 2. Sequencing results
demonstrating mosaic GNA11
and GNAQ mutations. (a) Sanger
sequencing of skin biopsy showing a
very low peak in GNA11 at position
c.547C>T (p.Arg183Cys) (asterisk).
(b) Sanger sequencing of the same skin
biopsy deoxyribonucleic acid after
restriction enzyme digest of the
normal allele, and hemi-nested
amplification, revealing the mutation
(asterisk). (c) Targeted next-generation
sequencing showing low allele
percentage mutations in skin but
undetectable in blood, GNA11
c.547C>T (p.Arg183Cys) in 5%
of reads. (d) GNAQ c.548G>A
(p.Arg183Gln) in 6% of reads from
skin but undetectable in blood.
www.jidonline.org 773
Figure 3. Mutant GNA11 leads to
activation of downstream signaling
pathways. (a) Western blot for Flag,
total GNA11, and the phosphorylated
and total p38, JNK, ERK and AKT in
total protein lysates from HEK293T
cells transfected with either vector,
wild-type GNA11 (WT), or one of two
mutants R183C or Q209L mutant
GNA11. (b) Ratio of phosphorylated
to total p38, JNK, ERK, and AKT
normalized by actin loading control.
Bars indicate 1 standard deviation.
*P < 0.05, unpaired t-test.
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774extra-cutaneous complications, by elucidating the underlying
genetic cause. We show here that extensive dermal melano-
cytosis and PPV are genetic conditions associated with post-
zygotic mutations in genes encoding Ga subunits of
heterotrimeric G proteins. Specifically, postzygotic mutations
in GNAQ have been found in extensive dermal melanocy-
tosis, and mutations in GNA11 or GNAQ have been found in
PPV types I, II (cesioflammea), IV, and V (cesiomarmorata), as
well as the unclassifiable achromico-melano-marmorata type.
Type IV is considered to be exceptionally rare and was not
tested because no samples were available. Type III (spilorosea)
is distinguished clinically from all other types of PPV by the
absence of dermal melanocytosis, and because only one pa-
tient from this group was tested (and was WT), we cannot yet
conclude anything about the genetic etiology of this type. Of
note, the percentage mosaicism was often very low, the result
of very few mutant cells within a skin biopsy of a completely
macular birthmark, thus emphasizing the need for adequately
sensitive detection techniques in this type of genetic disease. A
possible alternative explanation for our findings is that these
patients are somehow genetically predisposed to somatic
mutations in the same genes, and this is particularly relevant
for those in whom we have only been able to obtain one
sample. Although this cannot be entirely excluded, it is a
much less convincing explanation of the results than post-
zygotic mosaicism, as we discovered different mutations in
different patients, but the same mutation was present in more
than one location when two samples were obtained from one
individual. As candidate gene sequencing was performed in
this study, we cannot exclude the presence of further mutation
in other genes. Further exome sequencing could be performed
to look for secondary mutations.
True embryonic mosaicism has not yet been described for
GNA11 mutations. Isolated somatic GNA11 mutations haveJournal of Investigative Dermatology (2016), Volume 136been found in uveal melanoma and single blue nevi (a lesion
distinct from dermal melanocytosis both clinically and histo-
logically) (Van Raamsdonk et al., 2010). In contrast to our
findings in PPV, the prevalence of codon 183mutations in single
melanomas and blue nevi was much lower than of codon 209
mutations (Van Raamsdonk et al., 2010). Postzygotic mosaicism
for GNAQ mutations has been described as the major cause of
SWS, a purely vascular disorder with no pigmentary phenotype.
Somatic mutations in GNAQ are frequent in uveal melanoma
and single blue nevi (Van Raamsdonk et al., 2009). Therefore,
our findings not only describe GNA11 mosaicism but also
extend the phenotypic spectrum of human GNAQ mosaicism
from SWS (vascular only), through to PPV (vascular and
pigmentary), to extensive dermal melanocytosis (pigmentary
only). Exactly how the same mutation can generate these three
distinct phenotypes is not yet clear.
Codon 183 in both GNA11 and GNAQ is located within
the guanosine triphosphate binding region of the human Ga
subunit, a region required for hydrolysis of guanosine
triphosphate to guanosine diphosphate and an essential step
for inactivation of G-protein coupled receptor signaling.
Therefore, these mutations lead to decreased function of
guanosine triphosphatase and to constitutive activation of
downstream effector pathways. We have shown that the most
common mutation at codon 183 of GNA11 activates the
downstream p38 MAPK pathway in human cells, whereas the
codon 209 mutant (not found in this cohort in GNA11 but in
one patient in GNAQ) activates p38 MAPK, JNK and ERK
pathways, broadly supporting previous findings of effects of
mutations in both GNA11 (Li et al., 2014; Van Raamsdonk
et al., 2010) and GNAQ (Van Raamsdonk et al., 2010).
Of interest, different mutations in GNA11 in the germline
leading to altered sensitivity of cells to extracellular calcium
concentrations have been described in autosomal dominant
GNA11Q209L
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Figure 4. Mosaic expression of
GNA11 promotes ectopic pigmentary
lesions in zebrafish. (a) Images of
adult zebrafish mosaic for GNA11,
GNA11R183C, or GNA11Q209L
expression. Large, ectopic pigmentary
lesions are indicated next to white
arrows. Dashed box indicates zoomed
areas that show detail of pigmentary
lesions. (b) Numbers of pigmentary
lesions per fish expressing GNA11,
GNA11R183C, or GNA11Q209L. Dark
circles indicate ectopic pigmentary
lesions. White circles indicate fish
without pigmentary lesions. (c)
Histology hematoxylin and eosin
staining of a wild-type and
GNA11R183C zebrafish skin at 100
and 400 magnification. Melanocytes
are clearly visible in the dermis by
the black melanin (blue arrows),
frequently also in the epidermis (not
shown) and in a few cases within
underlying muscle (yellow arrow).
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GNA11 and GNAQ Mosaicismhypoparathyroidism and hypocalciuric hypercalcemia,
respectively (Nesbit et al., 2013). One of these mutations
(GNA11R60L) has been characterized as less activating than
GNA11Q209L (Li et al., 2014). This pattern of less severe
mutations being supportable in the germline, whereas more
severe mutations can survive only by mosaicism, once again
confirms Happle’s established theory (Happle, 1987). Patients
with PPV and SWS have not been documented to have ab-
normalities of calcium homeostasis; however, intravascular
calcification can be a feature of neurological abnormalities in
PPV, which could hypothetically involve localized mosaic
calcium imbalances. This is an area that merits future careful
research.A causal link between our genetic findings and mechanism
is strongly supported by the mosaic zebrafish models
demonstrated here, in which expression of GNA11R183C or
GNA11Q209L leads to ectopic and increased numbers of
melanocytes in the epidermal and dermal layers, recapitu-
lating the human phenotype of dermal melanocytosis.
Overexpression of WT GNA11 in melanocytes also leads to a
low level of pigmentary mosaicism in zebrafish, underscoring
the importance of close regulation of G-protein coupled re-
ceptor signaling in the melanocyte lineage. No other mosaic
animal models of GNA11 gain-of-function mutations exist;
however, further conformation of our findings comes from
germline hypermorphic alleles of GNA11, which lead towww.jidonline.org 775
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776increased cutaneous pigmentation in the murine Dsk
phenotype (Van Raamsdonk et al., 2004).
We found no evidence for the now-retracted theory of twin
spotting or didymosis. Rather, we have shown that a single
somatic mutation in GNA11 or GNAQ is responsible for both
types of cutaneous lesion in PPV, mirroring closely the
pathogenesis of the disparate birthmarks seen in HRAS
mosaicism (Groesser et al., 2013). We propose that extensive
dermal melanocytosis and PPV are members of an expanding
group of heterotrimeric G-protein alpha subunit gene mosaic
conditions, joining McCune-Albright syndrome (Weinstein
et al., 1991), caused by mosaicism for gain-of-function mu-
tations in GNAS, and SWS, caused by mosaic gain-of-
function mutations in GNAQ (Shirley et al., 2013). We also
propose that GNAQ mosaicism forms a spectrum from SWS,
through PPV, to extensive dermal melanocytosis. This
knowledge will allow accurate clinical molecular diagnosis
of a subset of extensive dermal melanocytosis and of PPV,
leading to identification of neonates at risk for serious com-
plications associated with these birthmarks. Importantly, it
will also pave the way for therapeutic options in these
children.
MATERIALS AND METHODS
All human and animal studies were approved by the authors’ in-
stitutions’ research ethics review boards. Declaration of Helsinki
protocols were followed, and all patients gave written informed
consent. Eleven patients from four international centers were
recruited with written consent for genetic research, approved by the
local research ethics committees. Patients were classified by clinical
phenotype: three with extensive or atypical dermal melanocytosis
(which was defined as involving areas other than only the lumbo-
sacral lesion) and eight with PPV, with representatives of subtypes I,
II (cesioflammea), III (spilorosea), and V (cesiomarmorata)
(Supplementary Table S1 and Figure 1), and also the unclassifiable
achromico-melano-marmorata type (Boente Mdel et al., 2008).
Blood samples and skin biopsies were taken from each patient, and
in those patients with PPV, skin was biopsied from both the vascular
and pigmentary birthmarks when possible.
Selective amplification of mutant alleles of candidate genes
GNA11 and GNAQ for Sanger sequencing
Deoxyribonucleic acid (DNA) was extracted from whole blood and
directly from fresh skin lesion samples using the DNeasy Blood and
Tissue Kit (Qiagen, Du¨sseldorf, Germany) and from paraffin
embedded tissue using the RecoverAll total nucleic acid extraction
kit for formalin-fixed paraffin-embedded tissue (Life Technologies,
Carlsbad, CA). To maximize detection of mutant alleles at low per-
centage mosaicism, we designed restriction enzyme digests of the
normal allele at hotspots codons 183 and 209 of GNA11 and 183 of
GNAQ using validated methods (Kinsler et al., 2013) and Sanger
sequencing. Primer sequences and restriction enzymes for each
hotspot are given in Supplementary Table S3 (online). Touchdown
polymerase chain reaction programs were used throughout, with 35
cycles for the first polymerase chain reaction and 25 for the second.
Targeted deep sequencing of GNA11 and GNAQ and
data analysis
We performed targeted deep sequencing of the regions spanning
mutations previously identified by selective amplification of mutant
alleles in all samples for which DNA quality was sufficient (asJournal of Investigative Dermatology (2016), Volume 136determined by the presence of a band above 10 kb size on agarose
gel). In subjects with no identified mutation, all coding regions of
GNAQ and GNA11 were screened using the same method. Targeted
regions were amplified using custom intronic primers and standard
long-range polymerase chain reaction protocols. Polymerase chain
reaction products were purified and libraries were prepared using
the Nextera XT DNA Sample Preparation kit (Illumina, Cambridge,
UK). Samples were then pooled and sequenced on a MiSeq instru-
ment (Illumina) according to the manufacturer’s recommendations
for paired-end 150-bp reads. In-depth sequencing was performed to
achieve a sequencing depth of at least 1,000 reads for all targeted
coding bases and splice junctions. Identification of candidate vari-
ants was performed as described previously (Riviere et al., 2012).
Briefly, all targeted bases were systematically screened to count all
sites with at least one read not matching the reference sequence,
using a base-quality threshold of 30. Candidate postzygotic variants
were confirmed by at least one independent experiment in all DNA
samples available from the patient.
Zebrafish model
To test the causality and model the effects of the mutation, we
injected zebrafish embryos with WT human GNA11, GNA11R183C,
or GNA11Q209L expressed from the melanocyte mitfa promoter and
grew the genetically mosaic animals to adulthood. All zebrafish
work was performed in accordance with United Kingdom Home
Office Animals (Scientific Procedures) Act (1986) and approved by
the University of Edinburgh Ethical Review Committee.
The human GNA11 cDNA clone was purchased from Origene
(purchased from NM_002067.1 precloned into an untagged
pCMV6-XL4 vector, catalog number SC303115). Mutant
GNA11Q209L (626a> t) was generated by site-directed genesis
polymerase chain reaction with primers (forward: 50-GATGT
GGGGGGCCTGCGGTCGGAGCGGAGG-30, reverse: 50-CCTC
CGCTCCGACCGCAGGCCCCCCACATC-30). Mutant GNA11R183C
(547c>t) was also generated with primers (forward: 50-CGTG
CTGCGGGTCTGCGTGCCCACCACCG-30, reverse: 50-CGGTGG
TGGGCACGCAGACCCGCAGCACG-30). The WT and mutant
GNA11 cDNAs were cloned together with the zebrafish mitfa gene
promoter into the pDestTol2CG2 expression vector using the Tol2kit
gateway cloning method (Kwan et al., 2007), resulting in mitfa-
GNA11, mitfa-GNA11Q209L and mitfa-GNA11R183C constructs. For
selection purposes, these constructs contain an additional green
fluorescent protein gene expressed from the heart cml promoter. Two
nanoliters of mixed mitfa-GNA11 plasmid DNA and Tol2 mRNA
(62.5 ng/ml and 70 ng/ml, respectively) was injected into one-cell
stage zebrafish embryos. Zebrafish embryos with green fluorescent
protein transgenic marker in the heart were selected and grown to
adulthood.
Adult zebrafish were anesthetized in 50 mg/L tricaine solution
and 1 images from both sides of the fish were taken under a
stereomicroscope. Dark patches of melanocyte lesions with
areas larger than that of one scale were counted. Adult zebrafish
were sacrificed by immersion in tricaine solution as directed by
Home Office Schedule 1 methods. Zebrafish were then dissected
in half transversely to increase penetration of the fixative and
fixed in 4% freshly prepared paraformaldehyde (Electron Micro-
scopy Sciences, Hatfield, PA) at 4 C for 3 days. Samples were
washed in phosphate buffered saline and decalcified in 0.5 M
EDTA at pH 8 for 5 days before storage in 70% ethanol. Samples
were embedded in paraffin wax and sectioned at 5-mm thickness.
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xylene twice for 5 minutes and then rehydrated through graded
alcohol solutions (100%, 90%, 70%, 50% and 30% for 3 minutes
each) and stopped in water. Slides were stained with Mayer he-
matoxylin and eosin after the standard hematoxylin and eosin
staining procedure.
Analysis of downstream effectors of GNA11 in human cell
line in culture
To characterize the functional effect of mutations on downstream
signaling pathways, HEK293T cells were transfected with vector, WT
GNA11, or mutant GNA11 constructs encoding R183C and Q209L.
The Q209L was used as a positive comparator because it is a more
studied mutation in GNA11. Flag-tagged GNA11 WT, R183C, and
Q209L constructs and vector alone control (pDEST26, Invitrogen,
Carlsbad, CA) were transfected into HEK293 cells using lipofect-
amine 2000 (Invitrogen), according to the manufacturer’s in-
structions. Cells were cultured for another 24 hours, and protein
lysates were prepared by boiling in a denaturing SDS buffer (2%
2-mercaptoethanol, 2% SDS, 10mM Tris pH 7.5) for 10 minutes.
Levels of GNA11 effector activation were assessed by western
blot using the following antibodies at the following concentrations:
Rabbit antiep-Serine473 Akt (1/500; Cell Signaling Technology,
Danvers, MA), rabbit anti-total Akt (1/1,000, Cell Signaling Tech-
nology), rabbit anti-phospho T180/Y182 p38 MAPK (1/500;
Cell Signaling Technology), rabbit anti-Total p38 MAPK (1/500,
Cell Signaling Technology), mouse anti-phospho T183/Y185
SAPK/JNK (1/500; Cell Signaling Technology), rabbit anti-total SAPK/
JNK (1/500; Cell Signaling Technology), pT202/Y204 ERK (1/500;
Cell Signaling Technology), and rabbit anti-total ERK 1,2 (1/1,000;
Cell Signaling Technology), mouse anti-Flag (DYKDDDDK tag)
(1/500; Cell Signaling Technology), rabbit anti-GNA11 (1/500;
GeneTex, Irvine, CA), and mouse anti-GAPDH (1/2,000; Millipore,
Watford, UK).
Primary antibody incubations were in TBST (100 mM Tris HCl, 0.2
M NaCl, 0.1% Tween-20 v/v) containing 5% bovine serum albumin
(Sigma, Gillingham, United Kingdom) or 5% skimmed milk powder
either overnight at 4 oC or for 1e2 hours at room temperature,
whereas secondary antibody incubations were performed in 5%
skimmed milk powder for 1 hour at room temperature. The con-
centrations used were swine anti-rabbit HRP (DakoCytomation,
Carpinteria, CA) 1:3,000 and rabbit anti-mouse HRP (DakoCyto-
mation) 1:2,000. Protein was visualized using Luminol reagent
(Santa Cruz Biotechnologies, Dallas, TX). Densitometry of bands
was performed using thresholded images in the ImageJ suite
(imagej.nih.gov/ij/).
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